Literature DB >> 11087782

An extended 5'-tau susceptibility haplotype in progressive supranuclear palsy.

J J Higgins1, L I Golbe, A De Biase, J Jankovic, S A Factor, R L Adler.   

Abstract

OBJECTIVE: To confirm the association of an extended 5'-tau haplotype on chromosome 17q with the disease phenotype in clinically ascertained individuals with sporadic progressive supranuclear palsy (PSP).
BACKGROUND: PSP is a neurodegenerative disease with parkinsonian signs accompanied by vertical supranuclear palsy and tau pathologic features. Previously, we documented the complete segregation of an extended 5'-tau haplotype consisting of four single nucleotide polymorphisms (SNP) with the disease phenotype in sporadic PSP. This study was conducted in an independent cohort to confirm these results and to improve the statistical power of the data. DESIGN AND METHODS: Direct sequencing and restriction enzyme digests were used to analyze four SNP in tau Exons 1, 4A, and 8. These contiguous SNP were used to reconstruct an extended 5'-tau haplotype in 52 affected and 54 age-matched control individuals.
RESULTS: The four SNP formed two homozygous 5'-tau haplotypes (HapA and HapC) or a heterozygous genotype. Fifty-one (98%) patients with PSP had HapA; one (2%) with a later onset was heterozygous; and none had HapC. These PSP haplotype frequencies were different (p < 0.00001) from those of the age-matched control group, in which 18 (33%) people had HapA; 26 (48%) were heterozygous; and 10 (19%) had HapC. The extended 5'-tau haplotype, HapA, had a high sensitivity (98%) and a moderate specificity (67%) as a marker for PSP.
CONCLUSIONS: A 5'-tau susceptibility haplotype may be a sensitive marker for sporadic PSP and a genetic defect in, or closely linked to, tau may contribute to the cause of PSP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087782     DOI: 10.1212/wnl.55.9.1364

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms.

Authors:  Stacey Melquist; David W Craig; Matthew J Huentelman; Richard Crook; John V Pearson; Matt Baker; Victoria L Zismann; Jennifer Gass; Jennifer Adamson; Szabolcs Szelinger; Jason Corneveaux; Ashley Cannon; Keith D Coon; Sarah Lincoln; Charles Adler; Paul Tuite; Donald B Calne; Eileen H Bigio; Ryan J Uitti; Zbigniew K Wszolek; Lawrence I Golbe; Richard J Caselli; Neill Graff-Radford; Irene Litvan; Matthew J Farrer; Dennis W Dickson; Mike Hutton; Dietrich A Stephan
Journal:  Am J Hum Genet       Date:  2007-03-08       Impact factor: 11.025

3.  H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers.

Authors:  Elisa Canu; Marina Boccardi; Roberta Ghidoni; Luisa Benussi; Cristina Testa; Michela Pievani; Matteo Bonetti; Giuliano Binetti; Giovanni B Frisoni
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

4.  Tau isoform regulation is region- and cell-specific in mouse brain.

Authors:  Pamela McMillan; Elena Korvatska; Parvoneh Poorkaj; Zana Evstafjeva; Linda Robinson; Lynne Greenup; James Leverenz; Gerard D Schellenberg; Ian D'Souza
Journal:  J Comp Neurol       Date:  2008-12-20       Impact factor: 3.215

5.  Linkage disequilibrium and haplotype tagging polymorphisms in the Tau H1 haplotype.

Authors:  Sofia A Oliveira; William K Scott; Fengyu Zhang; Jeffrey M Stajich; Kenichiro Fujiwara; Michael Hauser; Burton L Scott; Margaret A Pericak-Vance; Jeffery M Vance; Eden R Martin
Journal:  Neurogenetics       Date:  2004-06-08       Impact factor: 2.660

6.  Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.

Authors:  Naomi Kouri; Owen A Ross; Beth Dombroski; Curtis S Younkin; Daniel J Serie; Alexandra Soto-Ortolaza; Matthew Baker; Ni Cole A Finch; Hyejin Yoon; Jungsu Kim; Shinsuke Fujioka; Catriona A McLean; Bernardino Ghetti; Salvatore Spina; Laura B Cantwell; Martin R Farlow; Jordan Grafman; Edward D Huey; Mi Ryung Han; Sherry Beecher; Evan T Geller; Hans A Kretzschmar; Sigrun Roeber; Marla Gearing; Jorge L Juncos; Jean Paul G Vonsattel; Vivianna M Van Deerlin; Murray Grossman; Howard I Hurtig; Rachel G Gross; Steven E Arnold; John Q Trojanowski; Virginia M Lee; Gregor K Wenning; Charles L White; Günter U Höglinger; Ulrich Müller; Bernie Devlin; Lawrence I Golbe; Julia Crook; Joseph E Parisi; Bradley F Boeve; Keith A Josephs; Zbigniew K Wszolek; Ryan J Uitti; Neill R Graff-Radford; Irene Litvan; Steven G Younkin; Li-San Wang; Nilüfer Ertekin-Taner; Rosa Rademakers; Hakon Hakonarsen; Gerard D Schellenberg; Dennis W Dickson
Journal:  Nat Commun       Date:  2015-06-16       Impact factor: 14.919

Review 7.  Meta-analysis of the association between variants in MAPT and neurodegenerative diseases.

Authors:  Cheng-Cheng Zhang; Jun-Xia Zhu; Yu Wan; Lin Tan; Hui-Fu Wang; Jin-Tai Yu; Lan Tan
Journal:  Oncotarget       Date:  2017-07-04

8.  No evidence for association between tau gene haplotypic variants and susceptibility to Creutzfeldt-Jakob disease.

Authors:  Pascual Sánchez-Juan; Matthew T Bishop; Alison Green; Claudia Giannattasio; Alejandro Arias-Vasquez; Anna Poleggi; Richard S G Knight; Cornelia M van Duijn
Journal:  BMC Med Genet       Date:  2007-12-11       Impact factor: 2.103

9.  The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE ε4 Non-carriers.

Authors:  Pascual Sánchez-Juan; Sonia Moreno; Itziar de Rojas; Isabel Hernández; Sergi Valero; Montse Alegret; Laura Montrreal; Pablo García González; Carmen Lage; Sara López-García; Eloy Rodrííguez-Rodríguez; Adelina Orellana; Lluís Tárraga; Mercè Boada; Agustín Ruiz
Journal:  Front Aging Neurosci       Date:  2019-12-04       Impact factor: 5.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.